MULTIVARIATE ANALYSIS WITH EMPHASIS OF HER2/NEU EXPRESSION ON OVARIAN TUMORS IN A TERTIARY CARE HOSPITAL
DOI:
https://doi.org/10.22159/ajpcr.2025v18i4.54071Keywords:
Ovarian tumors, HER2/neu expression, Histopathological gradeAbstract
Objectives: The objective of the study was to evaluate immunohistochemical expression of HER2/NEU in ovarian tumors. Whether we can correlate HER2/NEU expression with the age of the patient, tumor size, histopathological type, and histopathological grade of the tumor.
Methods: Retrospective study was carried out for 2 years, ovarian specimens were received, grossing was done and evaluated with hematoxylin-eosin staining on 40 cases, and immunostaining with HER2/NEU was done on 32 cases of surface epithelial tumors.
Results: Out of 32 cases, HER2/NEU positivity was seen in 18 (56.5%) cases, and negativity was seen in 14 (43.5%) cases. Fifteen cases (46.8%) were serous type and 17 cases (53.2%) were mucinous serous ovarian tumors. A total of 18 cases had shown HER2/NEU positivity. In serous tumors, 0/+1 score was seen in 5(15%) benign (serous cystadenomas + serous adenofibromas) tumors, and in 1(3.1%) borderline, +2 score was seen in 2 (6.3%) borderline and +3 score was seen in 7 (21.8%) serous cystadenocarcinomas. In mucinous tumors, 6 (18%) benign (mucinous cystadenomas) and 2(6.3%) borderline tumors showed 0/+1 score. Score +2 was assigned to 5 (13.8%) benign (mucinous cystadenomas) tumors, 2(6.3%) mucinous cystadenocarcinomas and 2 (6.3%) mucinous cystadenocarcinomas shown +3 positivity
Conclusion: HER2/neu expression needs further evaluation to emerge as a prognostic indicator, which indicates disease progression, survival rate, and whether its overexpression can be correlated with the staging of the tumor or not in the near future. Prognostic significance of HER2/NEU is well established in breast carcinomas, unlike in ovarian carcinomas, which warranted further studies to establish its role.
Downloads
References
Tavassoli FA, Devilee P. Pathology and genetics of tumors of breast and female genital organs. In: World Health Organisation Classification of Tumors. Lyon: IARC Press; 2003. p. 123-4.
Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res. 2008;18:538-48.
Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: Overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748. PMC4170925 PMID:25276427
Rabban JT, Soslow RA, Christiana I, Charles Z. Immunohistology of the female genital tract. In: Dabbs DJ. Diagnostic Immunohistochemistry. 2nd ed. United Kingdom: Churchill Livingstone; 2006. p. 637-698.
Kacinski BM, Mayer AG, King BL, Carter D, Chambers SK. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecol Oncol. 1992;44(3):245-53.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/ college of American pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997-4013. doi: 10.1200/JCO.2013.50.9984
Marinas MC, Mogoş G, Ciurea R, Mogoş DG. EGFR, HER2-neu and Ki67 immunoexpression in serous ovarian tumours. Rom J Morphol Embryol. 2012;53(3):563-7.
Sueblinvong T, Manchana T, Khemapech N, Triratanachat S, Termrungruanglert W, Tresukosol D. Lack of prognostic significance of HER-2/neu in early epithelial ovarian cancer. Asian Pac J Cancer Prev. 2007;8(4):502-6.
Berchuck A, Kamel A, Whitaker B, Kerns B, Olt G, Kinney GA, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50:4087-91.
Eltabbakh H, Belinson JL, Kennedy AW, Casey CV, Tubbs RR. p53 and HER-2/neu overexpression in ovarian borderline tumors. Gynecol Oncol. 1997 May;65(2):218-24.
Garcia-Velasco A, Mendiola C, Sanchez-Munoz A, Ballestin C, Colomer R, Cortes-Funes H. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin Transl Oncol. 2008;10:367-71.
Goel S, Mehra M, Yadav A, Sharma M. Study of HER-2/neu Oncogene in benign and malignant ovarian tumors. Int J Sci Study. 2014;2(4):50-4.
Hellstrom I, Goodman G, Pullman J, Yang Y, Hellstrom KE. Overexpression of HER-2 in ovarian carcinomas. Cancer Res. 2001;61:2420-3.
Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer. 2004;14(6):1086-96.
Skírnisdóttir I, Sorbe B, Seidal T. The growth factor receptors HER-2/ neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer. 2001;11(2):119-29.
Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis. Am J Obstet Gynecol. 1993;168:162-9.
Plotkin A, Olkhov-Mitsel E, Huang WY, Nofech-Mozes S. Implementation of HER2 testing in endometrial cancer, a summary of real-world initial experience in a large tertiary cancer center. Cancer (Basel). 2024;16:2100. PMC11171265. doi: 10.3390/cancers16112100
Verria E, Guglielminia P, Puntonia M, Perdellib L, Papadiac A, Lorenzic P, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: Evaluation of its prevalence and prognostic significance, clinical Study. Oncology. 2005;68:154-61.
Peethambaram PP, Cliby WA, Lubiniecki G, Clayton AC, Roche PC, Iturria SJ, et al. Her-2/neu expression in ovarian cancer: Pre-and postexposure to platinum chemotherapy. Gynecel Oncol. 2003;89:99-104. doi: 10.1016/S0090-8258(03)00065-9
Pathak A, Singh M, Verma N. Role of epidermal growth factor receptor and ki67 in epithelial ovarian tumor. Asian J Pharm Clin Res. 2024;17(11):153-6.
Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, et al. Distribution of HER‐2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: From the Danish MALOVA ovarian cancer study. Cancer. 2003;98(1):66-73.
Published
How to Cite
Issue
Section
Copyright (c) 2025 DR. TILLAPUDI PRAVEENA TILLAPUDI
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
